[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
Read more 
Letter to the Shareholders – September 2021
Here is our September issue which echoes our #InvestorDay 2021. As usual, Philippe Genne has concocted an editorial entitled “Little GrassHopper”: a philosophical angle on the meaning of life and the importance of the individual in society.
Letter to our shareholders – November 2020
“Hunting in packs, a collaborative commercial approach hard-wired into Oncodesign’s genes” – Philippe Genne, President and CEO of Oncodesign.
Letter to our shareholders – April 2020
Here is our April 2020 issue which details the new organization of the Group into 3 Business Units. Interviews and articles on the menu. Anatomy of the new face of Oncodesign: BU Service, BU Biotech & BU Artificial Intelligence. Without forgetting the editorial by Ph. Genne entitled “how much is…
Letter to our shareholders – November 2019
“The alignment of planets is more topical than ever at the end of the year, with all due respect to the spell casters.” says Philippe Genne, CEO & founder, Oncodesign.
Letter to our shareholders – June 2019
“The health sector is in great need of innovations, & will continue to be for a long time yet” says Philippe Genne, CEO & founder, Oncodesign.
Letter to our shareholders – November 2018
“I urge you all to stay aboard and keep your eyes firmly fixed on the future: we believe in it” says Philippe Genne, CEO & founder, Oncodesign.
Letter to our shareholders – June 2018
“Step by step, we are building our future with innovation” says Philippe Genne, CEO & founder, Oncodesign.